scout

John L. Marshall, MD, The Ruesch Center for the Cure of GI Cancers

Articles by John L. Marshall, MD, The Ruesch Center for the Cure of GI Cancers

Cholangiocarcinoma: Potential Therapies Under Investigation

ByJohn L. Marshall, MD, The Ruesch Center for the Cure of GI Cancers,R. Kate Kelley, MD, University of California-San Francisco,Sameek Roychowdhury, MD, PhD, James Cancer Hospital & Solove Research Institute,Milind Javle, MD, The University of Texas MD Anderson Cancer Center

An overview of various treatment opportunities under study that are looking at using novel techniques to help personalize treatment for patients with bile duct cancers.

Implications for Using FGFR Inhibitors in Advanced CCA

ByJohn L. Marshall, MD, The Ruesch Center for the Cure of GI Cancers,R. Kate Kelley, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Sameek Roychowdhury, MD, PhD, James Cancer Hospital & Solove Research Institute,Milind Javle, MD, The University of Texas MD Anderson Cancer Center

Milind Javle, MD, of The University of Texas MD Anderson Cancer Center, explains what GI oncologists can expect from FGFR treatment for advanced cholangiocarcinoma in terms of treatment responses.

FGFR Inhibitors for Advanced Cholangiocarcinoma: Adverse Events

ByJohn L. Marshall, MD, The Ruesch Center for the Cure of GI Cancers,R. Kate Kelley, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Sameek Roychowdhury, MD, PhD, James Cancer Hospital & Solove Research Institute,Milind Javle, MD, The University of Texas MD Anderson Cancer Center

Recommendations for appropriately managing patients who experience adverse events associated with FGFR treatment for advanced cholangiocarcinoma.

FGFR Inhibitors for Advanced Cholangiocarcinoma

ByJohn L. Marshall, MD, The Ruesch Center for the Cure of GI Cancers,R. Kate Kelley, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Sameek Roychowdhury, MD, PhD, James Cancer Hospital & Solove Research Institute,Milind Javle, MD, The University of Texas MD Anderson Cancer Center

R. Kate Kelley, MD, of the UCSF Helen Diller Family Comprehensive Cancer Center, comments on the rationale for treating patients with advanced cholangiocarcinoma with an FGFR inhibitor.

Latest Updated Articles